. The EMPA-REG OUTCOME trial also reported long-term renal effects of empaglifozin in patients with T2D and established cardiovascular risk. Patients who received empaglifozin, in addition to standard care, had a significantly lower risk of progression to macroalbuminuria, doubling of the serum creatinine level and initiation of dialysis compared to placebo, although renal death and incidental microalbumunuria were not affected 4 .
The renoprotective effects of SGLT2 inhibitors are attributed to their ability to reduce renal hyperfiltration, by vasoconstriction of the afferent arteriole resulting in reduced intraglomerular pressure 5 . The renal benefits seen in the EMPA-REG OUTCOME trial may be due to the combined reduction in intraglomerular pressures as a result of SGLT2 mediated vasoconstriction of the afferent arteriole and RAAS drugs vasodilating the efferent arteriole 4 . A subsequent trial, CANVAS-R has demonstrated the renal benefits of canaglifozin over placebo in patients with T2D and heart disease, albeit with an increased risk of amputation 6 . SGLT2 inhibitors have been shown to be safe. Genital and urinary infections are the most frequently reported adverse effects, associated with the increased urinary excretion of glucose 3 . SGLT2 inhibitors are not associated with significant hypoglycaemia 7 . Some cases of euglycaemic diabetic ketoacidosis have been reported, but this is less of a concern in T2D 3 . Nephrologists are studying whether SGLT2 inhibitors can slow progression of chronic kidney disease while cardiologists are interested in these drugs to improve heart failure outcomes. SGLT2 inhibitors may be a useful treatment of diverse medical conditions.
